Veselaj Fahredin, Manxhuka-Kerliu Suzana, Neziri Arber, Shahini Labinot, Xharra Shefki, Selmani Liridon, Kerliu Lloreta, Kavaja Floren
Clinic of Urology, UCC of Kosovo, Prishtina, Kosovo.
Department of Pathology, UCC of Kosovo, Prishtina, Kosovo.
Open Access Maced J Med Sci. 2017 Apr 10;5(2):167-172. doi: 10.3889/oamjms.2017.035. eCollection 2017 Apr 15.
Clear cell renal cell carcinoma (CCRCC) is the most predominant renal tumour with unpredictable tumour behaviour. The aim of the study is to investigate the prognostic value of vascular endothelial growth factor A (VEGF-A) expression in CCRCC and to correlate it with other histological parameters as well as with patient's survival.
Tumour blocks were taken from 40 patients with histopathology diagnosis of CCRCC and tissue block from 20 normal kidneys as a control group were examined using the immuno-histochemical staining for VEGF-A.
The VEGF A expression in CCRCC was significantly higher than in the normal kidney tissues (U' = 720, P < 0.0001). VEGF A expression values in CCRCC were positively correlated with Disease Free Survival (r = 0.335, P = 0.034) and the tumor necrosis degree (r = 0.181, P = 0.262). VEGF-A expression values in CCRCC did not correlate with CD 31 expression (r = -0.09, P = 0.549), and Progression Free Survival (r = -0.07, P = 0.838). VEGF A expression values in CCRCC were negatively correlated with the tumor nuclear grade (r = -0.161, P = 0.318); the pathological tumor stage (r = -0.371, P = 0.018); the tumor size (r = -0.361, P = 0.022); the degree of tumor hemorrhage (r = -0.235, P = 0.143); and Cancer Specific Survival (r = -0.207, P = 0.713).
VEGF-A expression can be used to stratify advanced and metastatic CCRCC patients into low-benefit and high-benefit groups. Based on this study outcome it would be useful to perform IHC staining for VEGF-A expression in all patients with advanced and metastatic CCRCC.
透明细胞肾细胞癌（CCRCC）是最主要的肾肿瘤，其肿瘤行为难以预测。本研究旨在探讨血管内皮生长因子A（VEGF-A）表达在CCRCC中的预后价值，并将其与其他组织学参数以及患者生存率相关联。
从40例经组织病理学诊断为CCRCC的患者中获取肿瘤组织块，并以20例正常肾脏的组织块作为对照组，采用免疫组织化学染色检测VEGF-A。
CCRCC中VEGF A的表达显著高于正常肾组织（U' = 720，P < 0.0001）。CCRCC中VEGF A表达值与无病生存期呈正相关（r = 0.335，P = 0.034），与肿瘤坏死程度呈正相关（r = 我们 0.181，P = 0.262）。CCRCC中VEGF-A表达值与CD 31表达无相关性（r = -0.09，P = 0.549）,与无进展生存期无相关性（r = -0.07，P = 0.838）。CCRCC中VEGF A表达值与肿瘤核分级呈负相关（r = -0.161，P = 0.318）；与病理肿瘤分期呈负相关（r = -0.371，P = 0.018）；与肿瘤大小呈负相关（r = -0.361，P = 0.022）；与肿瘤出血程度呈负相关（r = -0.235，P = 0.143）；与癌症特异性生存期呈负相关（r = -0.207，P = 0.713）。
VEGF-A表达可用于将晚期和转移性CCRCC患者分为低获益组和高获益组。基于本研究结果，对所有晚期和转移性CCRCC患者进行VEGF-A表达的免疫组化染色将是有用的。
